Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters

Abstract

Aim: Antibody-drug conjugates (ADCs) feature an antibody recognizing a specific protein joined to a potent toxic payload. Numerous ADCs have received U.S. Food and Drug Administration (FDA) approval; however, clinical resistance arises. Resistance mechanisms include decreased expression or mutation of the antibody target, impaired payload release, or increased expression of adenosine triphosphate (ATP)-binding cassette (ABC) efflux transporters associated with multidrug resistance. We therefore sought to characterize the interactions of ABC multidrug transporters with ADC payloads.

Methods: We performed a high-throughput screen with 27 common ADC payloads using cell lines expressing ABC transporters P-glycoprotein [P-gp, encoded by ABC subfamily B member 1 (ABCB1)] or ABC subfamily B member G2 (ABCG2, encoded by ABCG2). Confirmatory assays were also performed using cells transfected to express P-gp, ABCG2, or multidrug resistance-associated protein 1 (MRP1, encoded by ABCC1).

Results: Several commonly used ADC payloads were substrates of P-gp, including calicheamicin γ1, monomethyl auristatin E, mertansine (DM1), and ravtansine (DM4). All the pyrrolobenzodiazepines tested - SJG136, SGD-1882, SG2057, and SG3199 - were substrates of P-gp, ABCG2, and MRP1. The modified anthracyclines nemorubicin and its metabolite PNU-159682 were poorly transported by both ABCB1 and ABCG2 and displayed nanomolar to picomolar toxicity. Further, we found that the efficacy of the FDA-approved ADC mirvetuximab soravtansine, with DM4 as the toxic payload, was decreased in cell lines expressing P-gp. In contrast, Duocarmycin DM and PNU-159682 were exquisitely toxic to a panel of 99 cancer cell lines of varying origins.

Conclusion: Several commonly used ADC payloads can be transported by ABC transporters, potentially leading to transporter-mediated drug resistance in patients. Future ADCs should be developed using payloads that are not ABC transporter substrates.

Keywords

ABC transporter / P-glycoprotein / ABCG2 / antibody-drug conjugate / drug resistance

References

[1] He J,Wang C,Li Y.Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.MedComm2024;5:e671 PMCID:PMC11283588

[2] Strebhardt K.Paul Ehrlich’s magic bullet concept: 100 years of progress.Nat Rev Cancer2008;8:473-80

[3] Sievers EL, Larson RA, Stadtmauer EA, et al.; Mylotarg Study Group. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.J Clin Oncol2001;19:3244-54

[4] Senter PD.The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.Nat Biotechnol2012;30:631-7

[5] Amiri-Kordestani L,Xu QC.FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.Clin Cancer Res2014;20:4436-41

[6] Modi S, Jacot W, Yamashita T, et al.; DESTINY-Breast04 Trial Investigators. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.N Engl J Med2022;387:9-20 PMCID:PMC10561652

[7] Meric-Bernstam F,Oaknin A.Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial.J Clin Oncol2024;42:47-58 PMCID:PMC10730032

[8] Caimi PF,Alderuccio JP.Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol2021;22:790-800

[9] Yu EY,O’Donnell PH.Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial.Lancet Oncol2021;22:872-82

[10] Moore KN, Angelergues A, Konecny GE, et al.; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer.N Engl J Med2023;389:2162-74

[11] Xi M,Zhang F.Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads.Eur J Med Chem2024;276:116709

[12] Jiang M,Xu B.Spotlight on ideal target antigens and resistance in antibody-drug conjugates: strategies for competitive advancement.Drug Resist Updat2024;75:101086

[13] Loganzo F,Gerber HP.Mechanisms of resistance to antibody-drug conjugates.Mol Cancer Ther2016;15:2825-34

[14] Zou Y,Chen B.crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer.Drug Resist Updat2024;77:101126

[15] Gandullo-Sánchez L.An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs.Cancer Lett2023;554:216024

[16] Saleh K,Khalife N.Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer.Cancer Drug Resist2024;7:22 PMCID:PMC11267152

[17] Walter RB,van der Velden VH.CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.Blood2007;109:4168-70 PMCID:PMC1885511

[18] Scaltriti M,Ocaña A.Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.J Natl Cancer Inst2007;99:628-38

[19] Ríos-Luci C,Díaz-Rodríguez E.Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity.Cancer Res2017;77:4639-51

[20] Linenberger ML,Flowers D.Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin.Blood2001;98:988-94

[21] Tang R,Perrot JY.P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.BMC Cancer2009;9:199 PMCID:PMC2708190

[22] Chen R,Newman E.CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin.Mol Cancer Ther2015;14:1376-84 PMCID:PMC4458438

[23] Robey RW,Qiu J,Bates SE.Rapid detection of ABC transporter interaction: potential utility in pharmacology.J Pharmacol Toxicol Methods2011;63:217-22 PMCID:PMC3086650

[24] Shen DW,Chin JE.Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification.Science1986;232:643-5

[25] Robey RW,van de Laar A.A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).Biochim Biophys Acta2001;1512:171-82

[26] Lee TD,Brimacombe KR.A high-throughput screen of a library of therapeutics identifies cytotoxic substrates of P-glycoprotein.Mol Pharmacol2019;96:629-40 PMCID:PMC6790066

[27] Inglese J,Jadhav A.Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries.Proc Natl Acad Sci U S A2006;103:11473-8 PMCID:PMC1518803

[28] Robey RW,Morisaki K.Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.Br J Cancer2003;89:1971-8 PMCID:PMC2394461

[29] Ishii M,Mitsui I.Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.Anticancer Drugs2000;11:353-62

[30] Naito K,Shigeno K.Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.Leukemia2000;14:1436-43

[31] Walter RB,Hong TC,Bernstein ID.Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.Blood2003;102:1466-73

[32] Walter RB,Thompson J.Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells.Leukemia2004;18:1914-7

[33] Cabaud O,Crompot E.Overcoming resistance to anti-nectin-4 antibody-drug conjugate.Mol Cancer Ther2022;21:1227-35

[34] Sun NY,Kim YS.Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma.bioRxiv2024; PMCID:PMC11482787

[35] Li WF,Weng HC.OBI-992, a novel TROP2-targeted antibody-drug conjugate, demonstrates antitumor activity in multiple cancer models.Mol Cancer Ther2025;24:163-75 PMCID:PMC11791482

[36] Chang TY,Wen SN.Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy.Sci Rep2025;15:8735 PMCID:PMC11906863

[37] Corbett S,Zammarchi F,van Berkel PH.The role of specific ATP-binding cassette transporters in the acquired resistance to pyrrolobenzodiazepine dimer-containing antibody-drug conjugates.Mol Cancer Ther2020;19:1856-65 PMCID:PMC7611352

[38] Yu SF,Go M.A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) That overcomes resistance to auristatin-based ADCs.Clin Cancer Res2015;21:3298-306

[39] Matsui H,Naito K.Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.Leukemia2002;16:813-9

[40] Kotono M,Takada-Owada A.Increased expression of ATP-binding cassette transporters in enfortumab vedotin-resistant urothelial cancer.IJU Case Rep2024;7:173-6 PMCID:PMC10909130

[41] Tang R,Perrot JY.Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML).BMC Cancer2008;8:51 PMCID:PMC2258302

[42] Marcelletti JF.A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.Cancer Chemother Pharmacol2023;92:369-80

[43] Chen R,Hou J.Inhibition of MDR1 overcomes resistance to brentuximab vedotin in hodgkin lymphoma.Clin Cancer Res2020;26:1034-44 PMCID:PMC7056527

[44] Thiruvengadam SK,Chen L.Phase I trial of brentuximab vedotin plus cyclosporine in relapsed/refractory hodgkin lymphoma.Clin Lymphoma Myeloma Leuk2024;24:724-31.e1

[45] Robey RW,Hall MD,Bates SE.Revisiting the role of ABC transporters in multidrug-resistant cancer.Nat Rev Cancer2018;18:452-64 PMCID:PMC6622180

[46] Giddens AC,Lu GL.Analogues of DNA minor groove cross-linking agents incorporating aminoCBI, an amino derivative of the duocarmycins: Synthesis, cytotoxicity, and potential as payloads for antibody-drug conjugates.Bioorg Med Chem2016;24:6075-81

[47] Elgersma RC,Huijbregts T.Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985.Mol Pharm2015;12:1813-35

[48] Scribner JA,Son T.Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer.Mol Cancer Ther2020;19:2235-44

[49] van der Lee MMC,Ubink R.The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers.Mol Cancer Ther2015;14:692-703

[50] Turner N, Saura C, Aftimos P, et al.; TULIP Trial Investigators. Trastuzumab duocarmazine in pretreated human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: an open-label, randomized, phase III trial (TULIP).J Clin Oncol2025;43:513-23

[51] Lambert JM.Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.J Med Chem2014;57:6949-64

[52] Roth JS, Guo H, Chen L, et al. Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters. bioRxiv 2025. Available from: https://doi.org/10.1101/2025.05.22.651305 [accessed 12 Jan 2026].